Bulimia Nervosa Clinical Trial
Official title:
Efficiency of rTMS in Bulimia: a Controlled Randomized Study
Bulimia nervosa is defined by recurrent episodes of binge eating followed by compensatory
behaviors (such as induced vomiting) to prevent weight gain. It is a common and serious
disease for which current treatment strategies have to be improved.
The aim of this study is to assess whether a transcranial magnetic stimulation reduces
bulimic symptoms in a short term.
Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive outpatient technique of
brain stimulation, based on the delivery of the localized magnetic field. It is now widely
used a in a variety of neurological and psychiatric disorders.
Several clinical and pathophysiological studies suggest efficacy of rTMS on the reduction of
craving and/or addictive behavior in various addictions such as alcoholism, smocking or
cocaine. Because of the addictive design of the BN, the effect of one session of rTMS on
food craving has been tested.
These studies show that stimulation of left dorsolateral prefrontal cortex (DPLPFC) under
high frequency decreases craving food. In addition, in a healthy subject, studies show that
rTMS appear to alter neuropsychological functions very involved in physiopathology of
bulimia. To date, the investigators do not know if rTMS cold be a useful treatment in the
treatment of bulimia. But in the light of these data, the investigators hypothesize that a
program of rtMS may have a therapeutic effect and therefore an interest for the treatment of
bulimia.
The objective of this project is to assess whether a program of repetitive transcranial
magnetic stimulation (rTMS) under high frequency at the left DLPFC reduces bulimic symptoms
in the short term.
This is a french multicenter study (Montpellier, Marseille, Saint Etienne), randomized,
single blind, two arm, in addition of a treatment already validated (prescription of
selective inhibitors of serotonin reuptake inhibitors (SSRIs)). The two arms are : one arm
with SSRI + rTMS and an arm with SSRI + sham rTMS (placebo), 30 patients per group will be
recruited.
The methodology includes:
1. an initial clinical and neuropsychological assessment.
2. 10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10
Hz and 110% of motor threshold intensity of the left DLPFC. Fifty percent of patients
will have a real stimulation and and the other fifty percent a sham stimulation.
Subjects will be randomized to one or other of the two groups. During the first and
last session a food challenge task will be administered before and after rTMS. Salivary
cortisol level will be assessed throughout the protocol.
3. the final clinical and neuropsychological assessment at 1 month (15 days minimum after
the last Session of rTMS).
The primary endpoint will focus on the number of binge within 15 days after the last session
of rTMS.
If the investigators hypothesis is confirmed the investigators will highlight a new
therapeutic modality in the treatment of bulimia. The secondary objectives will permit a
better understanding of the pathophysiology of the disorder and ways of possible therapeutic
actions of rTMS
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT02978742 -
Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder
|
N/A | |
Withdrawn |
NCT00988481 -
Topiramate Augmentation in Bulimia Nervosa Partial Responders
|
Phase 4 | |
Completed |
NCT00184301 -
A Comparison Study of Treatments Given to Patients With Concurrent Eating Disorder and Personality Disorder.
|
N/A | |
Completed |
NCT00522769 -
Cognitive Behavioral Therapy to Treat Bulimia Nervosa in Adolescents
|
Phase 1/Phase 2 | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Recruiting |
NCT04409457 -
Self-Control in Bulimia Nervosa
|
N/A | |
Recruiting |
NCT05509257 -
Naltrexone Neuroimaging in Teens With Eating Disorders
|
Early Phase 1 | |
Recruiting |
NCT05862389 -
Study on the Mechanism of Eating Disorder
|
||
Recruiting |
NCT05937243 -
Identifying Effective Technological-based Augmentations to Enhance Outcomes From Self-help Cognitive Behavior Therapy for Binge Eating
|
N/A | |
Recruiting |
NCT05728021 -
Smartphone-based Aftercare for Inpatients With Bulimia Nervosa
|
N/A | |
Completed |
NCT03781921 -
The Neural Bases of Emotion Regulation in Bulimia Nervosa
|
||
Completed |
NCT02553824 -
FDA Approved Medication to Reduce Binge Eating and/or Purging
|
Phase 1 | |
Terminated |
NCT04041024 -
Decision-making and Risk-taking in Bulimia
|
N/A | |
Completed |
NCT04265131 -
Emotion Regulation in Eating Disorders: How Can Art Therapy Contribute to Treatment Outcome?
|
N/A | |
Recruiting |
NCT06431854 -
Evaluation of a New Treatment Program for Adolescents With Eating Disorders: MINERVA Program
|
N/A | |
Recruiting |
NCT02960152 -
Periodontal Impact of Eating Disorders (the PERIOED Study)
|
N/A | |
Completed |
NCT00916071 -
Association Between Attention Deficit Hyperactivity Disorder and Bulimia Nervosa in Outpatients With Eating Disorders
|
N/A | |
Terminated |
NCT00308776 -
Cholecystokinin for Reducing Binge Eating in People With Bulimia Nervosa
|
N/A |